Personalis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.09.24	ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test (Businesswire)
19.08.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.06.24	ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring (Businesswire)
31.05.24	Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus (Businesswire)
22.05.24	Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 (Businesswire)
17.05.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.03.24	Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (Businesswire)
26.03.24	Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring (Businesswire)
19.03.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.02.24	Personalis Reports Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
14.02.24	Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
30.01.24	Personalis, ClearNote Health Join Hands To Advance Epigenomic Technology (RTTNews)
30.01.24	Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology (Businesswire)
17.01.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
16.01.24	Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay (Businesswire)
05.01.24	Personalis Expects Q4 Revenue To Grow 18% (RTTNews)
05.01.24	Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance (Businesswire)
04.12.23	Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives (Businesswire)
28.11.23	Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing (Businesswire)
26.10.23	Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer (Businesswire)
21.10.23	Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology (Businesswire)
19.10.23	Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023 (Businesswire)
18.10.23	Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance (Businesswire)
03.02.23	Personalis, Moderna Continue Partnership On Personalized Cancer Vaccine Program (RTTNews)
04.08.22	VNDA On Watch, NUVA Q2 Results Miss Estimates, MRTX Awaits FDA Decision... (RTTNews)
12.10.20	Growing NeXT: Personalis (PSNL) Hits All-Time High (RTTNews)
07.10.20	AXGT Reports Parkinson's Trial Data, CRBP Plunges As Cystic Fibrosis Study Fails, GMDA On Track (RTTNews)
22.06.20	This Day That Year: Personalis (PSNL) (RTTNews)
05.06.20	CYCN Awaits Sickle Cell Disease Data, TTPH Finalizes Its Suitor, ADMS Faces FDA In Feb (RTTNews)
23.12.19	Healthcare IPOs That Disappointed Investors In 2019 (RTTNews)
14.08.19	INMD In Steady Mode, PSNL Sees Rosy Outlook, QTRX On Watch (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.25	2.28 %	K V
Swiss Re	129.80	1.17 %	K V
Lonza Grp	526.00	0.88 %	K V
Logitech Intl	71.50	0.68 %	K V
UBS Group	28.46	0.57 %	K V
Alcon	76.24	-0.57 %	K V
Swiss Life Hldg	728.00	-0.76 %	K V
Givaudan	3’886.00	-1.20 %	K V
Novartis	92.40	-1.37 %	K V
Sonova Hldg	306.70	-1.73 %	K V

Nachrichten zu Personalis Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten